These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
942 related articles for article (PubMed ID: 27158275)
1. MGMT promoter methylation determined by HRM in comparison to MSP and pyrosequencing for predicting high-grade glioma response. Switzeny OJ; Christmann M; Renovanz M; Giese A; Sommer C; Kaina B Clin Epigenetics; 2016; 8():49. PubMed ID: 27158275 [TBL] [Abstract][Full Text] [Related]
2. MGMT promoter methylation in patients with glioblastoma: is methylation-sensitive high-resolution melting superior to methylation-sensitive polymerase chain reaction assay? Yamashita S; Yokogami K; Matsumoto F; Saito K; Mizuguchi A; Ohta H; Takeshima H J Neurosurg; 2019 Mar; 130(3):780-788. PubMed ID: 29726772 [TBL] [Abstract][Full Text] [Related]
3. Predictive impact of MGMT promoter methylation in glioblastoma of the elderly. Reifenberger G; Hentschel B; Felsberg J; Schackert G; Simon M; Schnell O; Westphal M; Wick W; Pietsch T; Loeffler M; Weller M; Int J Cancer; 2012 Sep; 131(6):1342-50. PubMed ID: 22139906 [TBL] [Abstract][Full Text] [Related]
4. Prognostic value of three different methods of MGMT promoter methylation analysis in a prospective trial on newly diagnosed glioblastoma. Christians A; Hartmann C; Benner A; Meyer J; von Deimling A; Weller M; Wick W; Weiler M PLoS One; 2012; 7(3):e33449. PubMed ID: 22428052 [TBL] [Abstract][Full Text] [Related]
5. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
6. MGMT promoter methylation in gliomas-assessment by pyrosequencing and quantitative methylation-specific PCR. Håvik AB; Brandal P; Honne H; Dahlback HS; Scheie D; Hektoen M; Meling TR; Helseth E; Heim S; Lothe RA; Lind GE J Transl Med; 2012 Mar; 10():36. PubMed ID: 22390413 [TBL] [Abstract][Full Text] [Related]
7. Intratumoral homogeneity of MGMT promoter hypermethylation as demonstrated in serial stereotactic specimens from anaplastic astrocytomas and glioblastomas. Grasbon-Frodl EM; Kreth FW; Ruiter M; Schnell O; Bise K; Felsberg J; Reifenberger G; Tonn JC; Kretzschmar HA Int J Cancer; 2007 Dec; 121(11):2458-64. PubMed ID: 17691113 [TBL] [Abstract][Full Text] [Related]
8. Correlation of apparent diffusion coefficient values measured by diffusion MRI and MGMT promoter methylation semiquantitatively analyzed with MS-MLPA in patients with glioblastoma multiforme. Sunwoo L; Choi SH; Park CK; Kim JW; Yi KS; Lee WJ; Yoon TJ; Song SW; Kim JE; Kim JY; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Chang KH J Magn Reson Imaging; 2013 Feb; 37(2):351-8. PubMed ID: 23023975 [TBL] [Abstract][Full Text] [Related]
9. Expression of glioma stem cell marker CD133 and O6-methylguanine-DNA methyltransferase is associated with resistance to radiotherapy in gliomas. He J; Shan Z; Li L; Liu F; Liu Z; Song M; Zhu H Oncol Rep; 2011 Nov; 26(5):1305-13. PubMed ID: 21769436 [TBL] [Abstract][Full Text] [Related]
10. Increased expression of the histone H3 lysine 4 methyltransferase MLL4 and the histone H3 lysine 27 demethylase UTX prolonging the overall survival of patients with glioblastoma and a methylated MGMT promoter. Kim J; Lee SH; Jang JH; Kim MS; Lee EH; Kim YZ J Neurosurg; 2017 May; 126(5):1461-1471. PubMed ID: 27367247 [TBL] [Abstract][Full Text] [Related]
11. Association of MGMT Promoter Methylation Status With Survival Outcomes in Patients With High-Risk Glioma Treated With Radiotherapy and Temozolomide: An Analysis From the NRG Oncology/RTOG 0424 Trial. Bell EH; Zhang P; Fisher BJ; Macdonald DR; McElroy JP; Lesser GJ; Fleming J; Chakraborty AR; Liu Z; Becker AP; Fabian D; Aldape KD; Ashby LS; Werner-Wasik M; Walker EM; Bahary JP; Kwok Y; Yu HM; Laack NN; Schultz CJ; Gray HJ; Robins HI; Mehta MP; Chakravarti A JAMA Oncol; 2018 Oct; 4(10):1405-1409. PubMed ID: 29955793 [TBL] [Abstract][Full Text] [Related]
12. The tumoral A genotype of the MGMT rs34180180 single-nucleotide polymorphism in aggressive gliomas is associated with shorter patients' survival. Fogli A; Chautard E; Vaurs-Barrière C; Pereira B; Müller-Barthélémy M; Court F; Biau J; Pinto AA; Kémény JL; Khalil T; Karayan-Tapon L; Verrelle P; Costa BM; Arnaud P Carcinogenesis; 2016 Feb; 37(2):169-176. PubMed ID: 26717998 [TBL] [Abstract][Full Text] [Related]
13. A five-miRNA signature with prognostic and predictive value for MGMT promoter-methylated glioblastoma patients. Cheng W; Ren X; Cai J; Zhang C; Li M; Wang K; Liu Y; Han S; Wu A Oncotarget; 2015 Oct; 6(30):29285-95. PubMed ID: 26320189 [TBL] [Abstract][Full Text] [Related]
14. The impact of MGMT methylation and IDH-1 mutation on long-term outcome for glioblastoma treated with chemoradiotherapy. Millward CP; Brodbelt AR; Haylock B; Zakaria R; Baborie A; Crooks D; Husband D; Shenoy A; Wong H; Jenkinson MD Acta Neurochir (Wien); 2016 Oct; 158(10):1943-53. PubMed ID: 27526690 [TBL] [Abstract][Full Text] [Related]
15. Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer. Barault L; Amatu A; Bleeker FE; Moutinho C; Falcomatà C; Fiano V; Cassingena A; Siravegna G; Milione M; Cassoni P; De Braud F; Rudà R; Soffietti R; Venesio T; Bardelli A; Wesseling P; de Witt Hamer P; Pietrantonio F; Siena S; Esteller M; Sartore-Bianchi A; Di Nicolantonio F Ann Oncol; 2015 Sep; 26(9):1994-1999. PubMed ID: 26113646 [TBL] [Abstract][Full Text] [Related]
16. An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity. Nguyen A; Legrain M; Noel G; Coca A; Meyer Ea N; Schott R; Lasthaus C; Chenard MP; Gaub MP; Lessinger JM; Guenot D; Entz-Werle N Curr Cancer Drug Targets; 2015; 15(7):624-40. PubMed ID: 26118907 [TBL] [Abstract][Full Text] [Related]
17. Relevance of MSP assay for the detection of MGMT promoter hypermethylation in glioblastomas. Yachi K; Watanabe T; Ohta T; Fukushima T; Yoshino A; Ogino A; Katayama Y; Nagase H Int J Oncol; 2008 Sep; 33(3):469-75. PubMed ID: 18695875 [TBL] [Abstract][Full Text] [Related]
18. Prognostic prediction of glioblastoma by quantitative assessment of the methylation status of the entire MGMT promoter region. Kanemoto M; Shirahata M; Nakauma A; Nakanishi K; Taniguchi K; Kukita Y; Arakawa Y; Miyamoto S; Kato K BMC Cancer; 2014 Aug; 14():641. PubMed ID: 25175833 [TBL] [Abstract][Full Text] [Related]
19. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Wick W; Meisner C; Hentschel B; Platten M; Schilling A; Wiestler B; Sabel MC; Koeppen S; Ketter R; Weiler M; Tabatabai G; von Deimling A; Gramatzki D; Westphal M; Schackert G; Loeffler M; Simon M; Reifenberger G; Weller M Neurology; 2013 Oct; 81(17):1515-22. PubMed ID: 24068788 [TBL] [Abstract][Full Text] [Related]
20. The number of methylated CpG sites within the MGMT promoter region linearly correlates with outcome in glioblastoma receiving alkylating agents. Siller S; Lauseker M; Karschnia P; Niyazi M; Eigenbrod S; Giese A; Tonn JC Acta Neuropathol Commun; 2021 Mar; 9(1):35. PubMed ID: 33663593 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]